Final answer:
Closed-system drug-transfer devices (CSTDs) must be used for the administration of Table 1 NIOSH antineoplastics and compounding.
Step-by-step explanation:
The use of closed-system drug-transfer devices (CSTDs) is essential for handling Table 1 NIOSH antineoplastics during both administration and compounding processes. CSTDs provide a closed and secure environment, minimizing the risk of exposure to hazardous drugs for healthcare workers and preventing the potential contamination of the surroundings.
These devices maintain a sealed system, ensuring the safe transfer and preparation of antineoplastic medications while adhering to the guidelines set by the National Institute for Occupational Safety and Health (NIOSH). By employing CSTDs, healthcare facilities can significantly enhance safety protocols, safeguarding both healthcare workers and patients from the inherent dangers associated with antineoplastic drugs.
The mandated use of closed-system drug-transfer devices for administering Table 1 NIOSH antineoplastics and compounding not only aligns with safety guidelines but also underscores a commitment to protecting healthcare professionals from occupational hazards and maintaining the integrity of pharmaceutical preparations in medical settings.